<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02652234</url>
  </required_header>
  <id_info>
    <org_study_id>SIM-ED-201504</org_study_id>
    <nct_id>NCT02652234</nct_id>
  </id_info>
  <brief_title>Study of Endostar Subcutaneous Injection in NSCLC</brief_title>
  <official_title>A Single-arm, Open-label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Endostar Subcutaneous Injection in Chinese Advanced NSCLC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm study to assess the safety, tolerability and&#xD;
      pharmacokinetics of Endostar subcutaneous injection in Chinese advanced NSCLC patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of adverse events</measure>
    <time_frame>until 30 days after the last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>day1, day2 of cycle1;day1,day2,day4,day13,day14,day15,day16,day17 of cycle2; day2,day13,day14,day15 of cycle3; up to 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>day1, day2 of cycle1;day1,day2,day4,day13,day14,day15,day16,day17 of cycle2; day2,day13,day14,day15 of cycle3; up to 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>day1, day2 of cycle1;day1,day2,day4,day13,day14,day15,day16,day17 of cycle2; day2,day13,day14,day15 of cycle3; up to 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>day1, day2 of cycle1;day1,day2,day4,day13,day14,day15,day16,day17 of cycle2; day2,day13,day14,day15 of cycle3; up to 9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>day1, day2 of cycle1;day1,day2,day4,day13,day14,day15,day16,day17 of cycle2; day2,day13,day14,day15 of cycle3; up to 9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Endostar-subcutaneous injection/Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <description>Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;</description>
    <arm_group_label>Endostar-subcutaneous injection/Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <arm_group_label>Endostar-subcutaneous injection/Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological/cytological confirmed unresectable stage ⅢB～Ⅳ non-squamous NSCLC&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy≥3 months&#xD;
&#xD;
          -  Adequate hematologic function: WBC≥3.0×109/L ,ANC≥1.5×10^9/L, Hb≥90g/L,&#xD;
             PLT≥100×10^9/L;&#xD;
&#xD;
          -  Adequate hepatic and renal function: ALT≤2.5×ULN, AST≤2.5×ULN, TBIL≤1.5×ULN,&#xD;
             creatinine≤1×ULN, creatinine clearance≥50ml/min;&#xD;
&#xD;
          -  Normal coagulation function (PT, APTT, TT, Fbg) ;&#xD;
&#xD;
          -  Patients signed informed consent form;&#xD;
&#xD;
          -  Willingness and capability to comply with protocol requirement and well communicate&#xD;
             with investigators.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With uncontrolled ascites or pleural effusion;&#xD;
&#xD;
          -  Patients receiving a chest or abdominal surgery within 28 days before enrollment; or&#xD;
             with not fully healed surgical incision; or expected to receive surgery during the&#xD;
             study;&#xD;
&#xD;
          -  History of ischemic or TIA within 6 months before enrollment;&#xD;
&#xD;
          -  Uncontrolled hypertension, hypertensive crisis or hypertensive encephalopathy;&#xD;
&#xD;
          -  Arrhythmias need to be treated; history of coronary artery disease (including angina&#xD;
             pectoris and myocardial infarction) or ischemic myocardium; congestive heart-failure&#xD;
             NYHA class ≥ II；&#xD;
&#xD;
          -  Serious active infections;&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, abdominal abscess within 6&#xD;
             months prior to enrollment;&#xD;
&#xD;
          -  Symptomatic brain or meningeal metastasis;&#xD;
&#xD;
          -  Epileptic seizure need to be treated;&#xD;
&#xD;
          -  HCV, HBV or HIV positive;&#xD;
&#xD;
          -  History of other malignant tumors within 5 years (except curable cervix carcinoma in&#xD;
             situ or skin basal cell carcinoma);&#xD;
&#xD;
          -  Known allergies to any excipient in the study drug;&#xD;
&#xD;
          -  Any conditions that may interfere with the patient's participation in the study or&#xD;
             have an impact on the assessment of the results of the study;&#xD;
&#xD;
          -  Any conditions that may endanger patient safety or interfere with the patient's&#xD;
             compliance;&#xD;
&#xD;
          -  Pregnant and lactating women;&#xD;
&#xD;
          -  The investigators consider the patients unsuitable for this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Province Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lingxiang Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Province Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanhong Zhu</last_name>
    <phone>86-025-85560000</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Jiangsu Province Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Chen</last_name>
    </contact>
    <contact_backup>
      <last_name>Lingxiang Chen</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>January 8, 2016</last_update_submitted>
  <last_update_submitted_qc>January 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endostar protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

